Read by QxMD icon Read


Raja R Narayan, John M Creasy, Debra A Goldman, Mithat Gönen, Cyriac Kandoth, Ritika Kundra, David B Solit, Gokce Askan, David S Klimstra, Olca Basturk, Peter J Allen, Vinod P Balachandran, Michael I D'Angelica, Ronald P DeMatteo, Jeffrey A Drebin, T Peter Kingham, Amber L Simpson, Ghassan K Abou-Alfa, James J Harding, Eileen M O'Reilly, Jean M Butte, Ryusei Matsuyama, Itaru Endo, William R Jarnagin
BACKGROUND: Although rare in the United States, gallbladder cancer (GBCA) is a common cause of cancer death in some parts of the world. To investigate regional differences in pathogenesis and outcomes for GBCA, tumor mutations were analyzed from a sampling of specimens. METHODS: Primary tumors from patients with GBCA who were treated in Chile, Japan, and the United States between 1999 and 2016 underwent targeted sequencing of known cancer-associated genes. Fisher exact and Kruskal-Wallis tests assessed differences in clinicopathologic and genetic factors...
November 14, 2018: Cancer
Serban Negoita, Angela Mariotto, Vicki Benard, Betsy A Kohler, Ahmedin Jemal, Lynne Penberthy
No abstract text is available yet for this article.
November 14, 2018: Cancer
Adriana C Vidal, Lauren E Howard, Amanda De Hoedt, Christopher J Kane, Martha K Terris, William J Aronson, Matthew R Cooperberg, Christopher L Amling, Stanislav Lechpammer, Scott C Flanders, Stephen J Freedland
BACKGROUND: In this study among men who underwent radical prostatectomy (RP), African American men (AAM) were 28% more likely to develop recurrent disease compared with Caucasian men (CM). However, among those who had nonmetastatic, castration-resistant prostate cancer (CRPC), race did not predict metastases or overall survival. Whether race predicts metastases among men who receive androgen-deprivation therapy (ADT) after a biochemical recurrence (BCR) (ie, before CRPC but after BCR) is untested...
November 14, 2018: Cancer
Katherine C Lee, Zara Cooper
No abstract text is available yet for this article.
November 14, 2018: Cancer
Rana R McKay, Lillian Werner, Susanna J Jacobus, Alexandra Jones, Elahe A Mostaghel, Brett T Marck, Atish D Choudhury, Mark M Pomerantz, Christopher J Sweeney, Susan F Slovin, Michael J Morris, Philip W Kantoff, Mary-Ellen Taplin
BACKGROUND: Abiraterone acetate suppresses adrenal androgens and glucocorticoids through the inhibition of CYP17; however, given the risk of mineralocorticoid excess, it is administered with glucocorticoids. Herein, the authors performed a phase 2, single-arm study that was designed to assess the safety of abiraterone acetate without steroids in patients with castration-resistant prostate cancer. METHODS: Eligible patients had castration-resistant prostate cancer with controlled blood pressure and normal potassium...
November 14, 2018: Cancer
Susan J Curry, Alex H Krist, Douglas K Owens
No abstract text is available yet for this article.
November 14, 2018: Cancer
Adi J Klil-Drori, Hui Yin, Laurent Azoulay, Alexa Del Corpo, Michaël Harnois, Michel-Olivier Gratton, Harold J Olney, Robert Delage, Pierre Laneuville, Luigina Mollica, Lambert Busque, Sarit E Assouline
BACKGROUND: In the current study, the authors determined whether adhering to molecular monitoring guidelines in patients with chronic myeloid leukemia (CML) is associated with major molecular response (MMR) and assessed barriers to adherent monitoring. METHODS: Newly treated patients with CML from the Quebec province-wide CML registry from 2005 to 2016 were included. Timely polymerase chain reaction (tPCR) was defined as the molecular assessment of BCR -ABL1 at the 3-month, 12-month, and 18-month time points from the initiation of tyrosine kinase inhibitor (TKI) therapy...
November 13, 2018: Cancer
Ira Surolia, Susan E Bates
No abstract text is available yet for this article.
November 13, 2018: Cancer
Dong Zhang, Charles E Matthews, Tiffany M Powell-Wiley, Qian Xiao
BACKGROUND: A growing body of research has demonstrated that individuals who live in neighborhoods with more severe socioeconomic deprivation may have higher risks for colorectal cancer (CRC). However, previous studies have examined neighborhood socioeconomic status (SES) at only 1 point in time, and it is unclear whether changes in neighborhood SES also can influence the risks of CRC. METHODS: Cox regression analysis was used to examine different trajectories of change in neighborhood SES over 10 years in relation to the incidence of CRC among 266,804 participants (ages 51-70 years) in the National Institutes of Health-AARP Diet and Health Study...
November 13, 2018: Cancer
Terhi V Ahvenainen, Netta M Mäkinen, Pernilla von Nandelstadh, Maija E A Vahteristo, Annukka M Pasanen, Ralf C Bützow, Pia M Vahteristo
BACKGROUND: Uterine leiomyomas (ULs) are the most common gynecologic tumors and affect 3 of every 4 women by the age of 50 years. The majority of ULs are classified as conventional tumors, whereas 10% represent various histopathological subtypes with features that mimic malignancy. These subtypes include cellular and mitotically active ULs and ULs with bizarre nuclei. Uterine leiomyosarcoma (ULMS), the malignant counterpart of UL, is an aggressive cancer with poor overall survival. The early diagnosis and preoperative differentiation of ULMS from UL are often challenging because their symptoms and morphology resemble one another...
November 13, 2018: Cancer
Debasish Sundi, Jeffrey J Tosoian, Yaw A Nyame, Ridwan Alam, Mary Achim, Chad A Reichard, Jianbo Li, Lamont Wilkins, Zeyad Schwen, Misop Han, John W Davis, Eric A Klein, Edward M Schaeffer, Andrew J Stephenson, Ashley E Ross, Brian F Chapin
BACKGROUND: Among men with localized high-risk prostate cancer (PCa), patients who meet very high-risk (VHR) criteria have been shown to experience worse outcomes after radical prostatectomy (RP) in a previous study. Variations of VHR criteria have been suggested to be prognostic in other single-center cohorts, but multicenter outcomes validating VHR criteria have not been described. This study was designed to validate VHR criteria for identifying which PCa patients are at greatest risk for cancer progression...
November 13, 2018: Cancer
Haller J Smith, Tyler R McCaw, Angelina I Londono, Ashwini A Katre, Selene Meza-Perez, Eddy S Yang, Andres Forero, Donald J Buchsbaum, Troy D Randall, J Michael Straughn, Lyse A Norian, Rebecca C Arend
BACKGROUND: Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in patients with ovarian cancer. The authors previously demonstrated that the histone deacetylase inhibitor entinostat increases MHCII expression on ovarian cancer cells. In the current study, they evaluated whether entinostat treatment and resultant MHCII expression would enhance beneficial immune responses and impair tumor growth in mice with ovarian cancer...
November 13, 2018: Cancer
Andrew M Brunner, Donna S Neuberg, Seth A Wander, Hossein Sadrzadeh, Karen K Ballen, Philip C Amrein, Eyal Attar, Gabriela S Hobbs, Yi-Bin Chen, Ashley Perry, Christine Connolly, Christelle Joseph, Meghan Burke, Aura Ramos, Ilene Galinsky, Katharine Yen, Hua Yang, Kimberly Straley, Sam Agresta, Sophia Adamia, Darrell R Borger, Anthony Iafrate, Timothy A Graubert, Richard M Stone, Amir T Fathi
BACKGROUND: Acute myeloid leukemia (AML) cells harboring mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) produce the oncometabolite 2-hydroxyglutarate (2HG). This study prospectively evaluated the 2HG levels, IDH1/2 mutational status, and outcomes of patients receiving standard chemotherapy for newly diagnosed AML. METHODS: Serial samples of serum, urine, and bone marrow aspirates were collected from patients newly diagnosed with AML, and 2HG levels were measured with mass spectrometry...
November 13, 2018: Cancer
Parth K Modi, Brent K Hollenbeck, Tudor Borza
No abstract text is available yet for this article.
November 12, 2018: Cancer
Zohor Levi, Yakir Rottenberg, Gilad Twig, Lior Katz, Adi Leiba, Estela Derazne, Dorit Tzur, Sapir Eizenstein, Lital Keinan-Boker, Arnon Afek, Jeremy Dan Kark
BACKGROUND: There is growing concern regarding the impact of adolescent obesity on adult health. The objective of this study was to evaluate the association between body mass index (BMI) in late adolescence and the incidence of pancreatic cancer during adulthood. METHODS: The authors analyzed a cohort of 1087,358 Israeli Jewish men and 707,212 Jewish women who underwent a compulsory physical examination between ages 16 and 19 years from 1967 to 2002. Pancreatic cancer incidence through December 31, 2012 was identified by linkage to the national cancer registry...
November 12, 2018: Cancer
Chanan Meydan
Malignancy and the metabolic syndrome are key challenges in modern health care. Population-based data registries are potent enablers for research into possible associations between them, providing primers for further studies, including the elucidation of molecular and cellular mechanisms underlying such links.
November 12, 2018: Cancer
Matthew J Resnick, Amy J Graves, Robert J Gambrel, Sunita Thapa, Melinda B Buntin, David F Penson
BACKGROUND: Despite the rapid diffusion of accountable care organizations (ACOs), the effect of ACO enrollment on cancer diagnosis, treatment, and survivorship remains unknown. The objective of this study was to determine whether Medicare Shared Savings Program (MSSP) ACO enrollment was associated with changes in screening for breast, colorectal, and prostate cancers. METHODS: The authors built a cohort of Medicare beneficiaries from 2006 through 2014 comprising 39,218,652 person-years of observation before and 17,252,345 person-years of observation after MSSP enrollment...
November 9, 2018: Cancer
László Tabár, Peter B Dean, Tony Hsiu-Hsi Chen, Amy Ming-Fang Yen, Sam Li-Sheng Chen, Jean Ching-Yuan Fann, Sherry Yueh-Hsia Chiu, May Mei-Sheng Ku, Wendy Yi-Ying Wu, Chen-Yang Hsu, Yu-Ching Chen, Kerri Beckmann, Robert A Smith, Stephen W Duffy
BACKGROUND: Women and their health care providers need a reliable answer to this important question: If a woman chooses to participate in regular mammography screening, then how much will this choice improve her chances of avoiding a death from breast cancer compared with women who choose not to participate? METHODS: To answer this question, we used comprehensive registries for population, screening history, breast cancer incidence, and disease-specific death data in a defined population in Dalarna County, Sweden...
November 8, 2018: Cancer
Kathleen P Hartnett, Ann C Mertens, Michael R Kramer, Timothy L Lash, Jessica B Spencer, Kevin C Ward, Penelope P Howards
BACKGROUND: The objective of this retrospective cohort study was to determine whether women who conceive soon after treatment for cancer have higher risks of adverse pregnancy outcomes. METHODS: Vital records data were linked to cancer registry diagnosis and treatment information in 3 US states. Women who conceived their first pregnancy after diagnosis between ages 20 and 45 years with any invasive cancer or ductal carcinoma in situ were eligible. Log-binomial models were used to compare risks in cancer survivors who conceived in each interval to the risks in matched comparison births to women without cancer...
November 7, 2018: Cancer
Ann H Partridge
No abstract text is available yet for this article.
November 7, 2018: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"